MYC and cancer: Surprisingly, the stabilization of both β-catenin and c-Myc observed in response to the dual GSK-3α/3β inhibitor SB-732881-H correlates with a paradoxical increase in c-Myc-mediated apoptosis in preclinical models of KRas-dependent human cancers, presenting a new perspective on the therapeutic implications of GSK-3 inhibitors [141].